newsfilter
← Latest News
Business Wire·

HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology

Milestone results formed the basis of HeartBeam's 12-lead ECG synthesis software application submitted to FDA in January 2025 HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming